Last reviewed · How we verify
Placebo then darvocet then opana
Placebo then darvocet then opana is a Opioid analgesic Small molecule drug developed by University of Rochester. It is currently FDA-approved for Moderate to severe pain (trial indication not fully specified). Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug.
This is a clinical trial sequence comparing placebo against two opioid analgesics (Darvocet and Opana) for pain relief.
This is a clinical trial sequence comparing placebo against two opioid analgesics (Darvocet and Opana) for pain relief. Used for Moderate to severe pain (trial indication not fully specified).
At a glance
| Generic name | Placebo then darvocet then opana |
|---|---|
| Also known as | opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug |
| Sponsor | University of Rochester |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | FDA-approved |
Mechanism of action
Darvocet (propoxyphene/acetaminophen) and Opana (oxymorphone) are both opioid receptor agonists that bind to mu-opioid receptors in the central nervous system to reduce pain perception. The trial design uses placebo as a control to assess the efficacy and safety of these marketed opioid medications in a specific patient population.
Approved indications
- Moderate to severe pain (trial indication not fully specified)
Common side effects
- Nausea
- Constipation
- Dizziness
- Drowsiness
- Respiratory depression
Key clinical trials
- Lumbar Stenosis Outcomes Research II (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo then darvocet then opana CI brief — competitive landscape report
- Placebo then darvocet then opana updates RSS · CI watch RSS
- University of Rochester portfolio CI
Frequently asked questions about Placebo then darvocet then opana
What is Placebo then darvocet then opana?
How does Placebo then darvocet then opana work?
What is Placebo then darvocet then opana used for?
Who makes Placebo then darvocet then opana?
Is Placebo then darvocet then opana also known as anything else?
What drug class is Placebo then darvocet then opana in?
What development phase is Placebo then darvocet then opana in?
What are the side effects of Placebo then darvocet then opana?
What does Placebo then darvocet then opana target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor
- Manufacturer: University of Rochester — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain (trial indication not fully specified)
- Also known as: opana: oxymorphone HCL, darvocet: propoxyphene/acetaminophen, placebo: inactive drug
- Compare: Placebo then darvocet then opana vs similar drugs
- Pricing: Placebo then darvocet then opana cost, discount & access